Related Experiment Video
Updated: Feb 28, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
Immunomodulatory Strategies for Huntington's Disease Treatment
Gabriela D Colpo1, Natalia P Rocha1, Erin Fur Stimming2
1Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.
Background & Objective:
Huntington's disease (HD) is an autosomal-dominant, progressive neurodegenerative disease characterized by selective loss of neurons in the striatum and cortex, which leads to progressive motor dysfunction, cognitive decline and behavioral symptoms. HD is caused by a trinucleotide (CAG) repeat expansion in the gene encoding the protein huntingtin. Despite the fact that the HD gene was identified over 20 years ago, there is no effective disease-modifying therapy for HD and only symptomatic therapies are available to date. Recently, new agents and procedures have been investigated for HD and many of them have focused on immunomodulatory and/or anti- inflammatory strategies.
Conclusion:
The objective of the current review is to summarize data on the therapeutic strategies to treat HD that are based on immunomodulatory effects.
Related Concept Videos
Tumor Immunotherapy
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Alzheimer's Disease: Treatment
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...

